FEMY FEMASYS INC

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, founder, president & chief executive officer, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest. The conference is being held virtually on June 20-22, 2023.

Kathy Lee-Sepsick will participate in a fireside chat with Jason McCarthy, senior managing director and head of biotechnology research at Maxim Group on June 22 at 9:00am ET.

This conference will be live on M-Vest. To attend, sign up to become an M-Vest member and register .

About Femasys

Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed in the United States include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit or follow us on , , and .

Contacts:

Investors

Chuck Padala

LifeSci Advisors, LLC

917-741-7792

Femasys Inc.

Investor Contact:

Media Contact:



EN
14/06/2023

Underlying

FEMYFEMASYS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FEMASYS INC

 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces Financial Results for Year Ended December 31, 2024, ...

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 a...

March 27, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces Partnership with CNY Fertility, National Conglomerat...

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations Femasys continues to expand access and market share for its first-line infertility treatment option ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces a partnership with CNY Fertility, a national provider of fertility services ...

March 19, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Secures Distribution Partnerships for Commercialization of Fem...

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain -- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the Company has secured strategic distribution partnerships for FemBloc® in ...

March 18, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces FemBloc Delivery System Approval in Europe; A Signif...

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach First-in-world approval of FemBloc delivery system for women seeking permanent birth control ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under...

March 13, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces Peer-Reviewed Publication of Positive Safety and Eff...

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials --Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the peer-...

February 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch